• ImmuCell posted net income of USD 1.94 million for quarter ended March 31, 2026, up 34.2%.
• Product sales climbed 28.4% to USD 10.36 million, driven by higher Tri-Shield and Dual Force volumes and price increases across most product lines.
• Net operating income rose 76.2% to USD 1.97 million as gross profit increased 38.9% to USD 4.66 million.
• Sales and marketing expense increased 43.9% to USD 1.23 million on higher wages and promotional and tradeshow spending, while administrative expense rose 82.7% to USD 1.14 million on higher executive compensation.
• Cash and cash equivalents totaled USD 6.81 million at March 31, up 79% from Dec. 31, while net cash from operating activities rose to USD 3.57 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017045), on May 14, 2026, and is solely responsible for the information contained therein.